Carolina Davide, MD
Family Medicine · Waianae, HINPI 1235170689
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 462 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 31.5% of the total. Among family medicine clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 462 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$702
- Novo Nordisk$621
- Bayer$536
- Amgen$534
- plus $2K from 16 others
What the payments were for
- Food & beverage$8,974100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 122 | $2,835 |
| GSK | 162 | $1,958 |
| Boehringer Ingelheim | 30 | $702 |
| Novo Nordisk | 35 | $621 |
| Bayer | 15 | $536 |
| Amgen(2 entities) | 18 | $534 |
| Lilly USA, LLC | 25 | $500 |
| Novartis | 19 | $449 |
| Merck | 9 | $188 |
| Ironwood Pharmaceuticals, Inc | 7 | $144 |
| Sanofi-aventis U.S. LLC | 3 | $130 |
| Kowa Pharmaceuticals America, Inc. | 5 | $97 |
| Insmed, Inc. | 1 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Johnson & Johnson | 2 | $40 |
| Pfizer | 1 | $38 |
| Exact Sciences | 1 | $28 |
| Irhythm Technologies, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Verona Pharma, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,989 in reported general payments places this provider in the 95th percentile of 376 family medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 144 | $154,489 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $62,205 |
| OzempicSemaglutide | 26 | $48,367 |
| JanuviaSitagliptin Phosphate | 32 | $39,593 |
| JardianceEmpagliflozin | 26 | $31,810 |
| EliquisApixaban | 18 | $21,945 |
| MounjaroTirzepatide | 13 | $19,279 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $17,009 |
| Atorvastatin Calcium | 652 | $13,258 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $10,433 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $8,135 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $7,662 |
| Losartan Potassium | 557 | $7,136 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,031 |
| Amlodipine Besylate | 384 | $4,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,835 | $179,161179 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $1,958 | $75,37195 claims |
| Novo NordiskOzempic | $621 | $48,36726 claims |
| MerckJanuvia | $188 | $39,59332 claims |
| Boehringer IngelheimJardiance | $702 | $31,81026 claims |
| PfizerEliquis | $38 | $21,94518 claims |
| Lilly USA, LLCMounjaro | $500 | $19,27913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 376 family medicine providers in Hawaii.
Other family medicine in Waianae
- Terri KakugawaWaianae$3K
- Ashley BaldaufWaianae$3K
- Meghann MartellyWaianae$2K
- Brian StolleyKihei$126K
- Vicente RamoHonolulu$34K
- Edward AlqueroWaipahu$24K
- Noelani HobbsWaipahu$23K
- Rainier Dennis BautistaLihue$23K
- Choon YeoHonolulu$20K
- Buddy FesterlingHilo$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.